A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)

Trial Identifier: 3475-04A
Sponsor: MSD
Start Date: November 2022
Primary Completion Date: October 2027
Study Completion Date: October 2027

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Protocol Plain Language Summary

Trial Locations

Country Location
Australia, Queensland Brisbane, Queensland, Australia, 4029
Chile, Region M. de Santiago Santiago, Region M. de Santiago, Chile, 8420383
Chile, Region M. de Santiago Santiago, Region M. de Santiago, Chile, 6900941
Denmark, Hovedstaden Copenhagen, Hovedstaden, Denmark, 2100
Israel, N/A Haifa, N/A, Israel, 3109601
Israel, N/A Petah Tikva, N/A, Israel, 4941492
Israel, N/A Ramat Gan, N/A, Israel, 5265601
Korea, Republic of, Seoul Seoul, Korea, Republic of, 05505
Korea, Republic of, Seoul Seoul, Korea, Republic of, 06351
Korea, Republic of, Seoul Seoul, Korea, Republic of, 03722
Spain, Barcelona Barcelona, Spain, 08035
Spain, Madrid Madrid, Spain, 28040
United States, CA Orange, CA, United States, 92868
United States, CO Aurora, CO, United States, 80045
United States, IN Indianapolis, IN, United States, 46202
United States, MO St. Louis, MO, United States, 63110
United States, OH Cleveland, OH, United States, 44195
United States, PA Pittsburgh, PA, United States, 15232